US Edition
Sandoz Expanding Production in Slovenia
13 Articles
13 Articles
der Standard AT
der Standard DEThe Swiss pharmaceutical company with only penicillin production in the western world in Kundl invests 400 million in strengthening the biosimilar division near Ljubljana
Globe Newswire
Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
MEDIA RELEASE Investment marks latest step in strategic plan to capture significant part of unprecedented biosimilar patent-expiry market opportunity of...
Sandoz expanding production in Slovenia
Sandoz, a Swiss pharma group specialising in generics and biosimilars, is expanding in Slovenia by building a €400 million high-tech plant for the production of biosimilars near Ljubljana airport. Slated for completion in three years, it will create over 260 new jobs by 2029. "The investment connects the entire supply of biosimilars from Slovenia to patients in Slovenia, Europe and around the world," Gregor Makuc, President of Sandoz Slovenia, s…
Sandoz is expanding its presence in Slovenia. The Basel-based generic drug giant has launched construction of a new biosimilar production center in Brnik, an investment of $440 million.
Coverage Details
Bias Distribution
- 89% of the sources lean Left
To view factuality data please Upgrade to Premium
